In the July 19 article “Platinum drugs are off the shortage list, but the underlying problem is unsolved,” FDA Commissioner Robert Califf and others describe a solution to the U.S. drug shortage as a matter of paying more for generic drugs.
To the editor, I was not booed off the stage. Rather, the response was incredibly enthusiastic. After my session people lined up for over 45 minutes to talk to me. Many thanked me for publicizing this issue, indicating that the problems with the Illumina platform have been apparent to many, but no one else was... […]
On Oct. 13, 2023, the world mourned the loss of Dr. Mohammed Dabbour, an exceptionally kind and dedicated individual with aspirations. I was deeply saddened to learn about the tragic passing of a colleague, along with several members of his family, including his son and father.
A letter to the editor by The Philadelphia Inquirer’s James Neff raises concerns about conflicts of interest in a recent Guest Editorial published in The Cancer Letter. The authors and The Cancer Letter editor respond.
The UCSD Moores Cancer Center External Advisory Board is extremely disappointed in the commentary included in the most recent issue of The Cancer Letter regarding MCC.
As Case Comprehensive Cancer Center’s new director, and on behalf of our membership, I applaud the Biden administration for tapping Monica Bertagnolli, MD, FASCO, as the second female director of the National Institutes of Health (NIH) and congratulate Dr. Bertagnolli on her candidacy.
According to the NCI study, the number of people who live outside the catchment areas of NCI-designated cancer centers is estimated at about 40 million. According to the AACI-Jefferson study, the number of people who live outside catchment areas of the AACI member cancer centers is estimated at about 25 million.
My first ASCO memories were back almost four decades ago (The Cancer Letter, June 3, 2022).
Karen E. Knudsen, MBA, PhD President, Association of American Cancer Institutes Enterprise director, Sidney Kimmel Cancer Center at Jefferson In a year of monumental health care and operational challenges for cancer centers, the Association of American Cancer Institutes marks with enthusiasm the electoral victory of a presidential candidate who has proven his unyielding commitment to defeating cancer.
I was disappointed to see that you reported on the results of the IMpassion 131 trial, without context. [The Cancer Letter, Sept. 4, 2020]
